文献速递临床试验与 GCP流行病学与生物统计

绝经激素治疗的长期认知影响:KEEPS延续研究结果

Long-term cognitive effects of menopausal hormone therapy: Findings from the KEEPS Continuation Study.
PubMed 文献 · PLoS Med · 2024-11-21

KEEPS延续研究在KEEPS-Cog试验结束约10年后,对275名参与者重新评估认知,发现与安慰剂相比,早期绝经后短期使用口服结合马雌激素或经皮雌二醇均无长期认知获益或损害,基线认知和试验期间认知变化是最强预测因素。

要点

  • 早期绝经后短期使用绝经激素治疗约10年后未显示长期认知获益或损害。
  • 基线认知和KEEPS试验期间认知变化是后续认知表现的最强预测因素。
  • 对健康、近期绝经女性,绝经激素治疗用于症状管理的长期神经认知安全性令人安心。

核心结论

  • 早期绝经后开始短期绝经激素治疗与安慰剂相比无长期认知影响。
  • 绝经激素治疗不改善或保护该人群的认知功能,但也不造成长期认知损害。

研究设计与样本

  • KEEPS延续研究是KEEPS临床试验的观察性纵向队列研究,于2017年至2022年对KEEPS参与者进行面对面随访。
  • KEEPS-Cog(2005-2008)将参与者随机分为口服结合马雌激素0.45 mg/d组、经皮雌二醇50 μg/d组(两组均联用微粒化黄体酮200 mg/d每月12天)或安慰剂组,治疗48个月。
  • KEEPS延续研究邀请原727名中的622名女性,最终7个中心共299名入组,275名有KEEPS和KEEPS延续研究的认知数据。

主要发现

  • 潜在增长模型显示几乎所有认知领域的截距和斜率显著相关,表明认知因子得分随时间变化。
  • 评估绝经激素治疗分配对KEEPS期间及包括KEEPS延续研究访视在内的所有随访年份认知斜率影响的检验均无统计学意义。
  • 横断面比较确认,随机分配至绝经激素治疗组(口服结合马雌激素和经皮雌二醇组)的参与者在治疗结束后约10年的认知表现与安慰剂组相似。

临床怎么用

  • 原文结论提示,对健康、近期绝经女性,绝经激素治疗用于症状管理的长期神经认知安全性令人安心。
  • 原文结论提示,绝经激素治疗不改善或保护该人群的认知功能。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Findings from Kronos Early Estrogen Prevention Study (KEEPS)-Cog trial suggested no cognitive benefit or harm after 48 months of menopausal hormone therapy (mHT) initiated within 3 years of final menstrual period. To clarify the long-term effects of mHT initiated in early postmenopause, the observational KEEPS Continuation Study reevaluated cognition, mood, and neuroimaging effects in participants enrolled in the KEEPS-Cog and its parent study the KEEPS approximately 10 years after trial completion. We hypothesized that women randomized to transdermal estradiol (tE2) during early postmenopause would show cognitive benefits, while oral conjugated equine estrogens (oCEE) would show no effect, compared to placebo over the 10 years following randomization in the KEEPS trial. METHODS AND FINDINGS: The KEEPS-Cog (2005-2008) was an ancillary study to the KEEPS (NCT00154180), in which participants were randomized into 3 groups: oCEE (Premarin, 0.45 mg/d), tE2 (Climara, 50 μg/d) both with micronized progesterone (Prometrium, 200 mg/d for 12 d/mo) or placebo pills and patch for 48 months. KEEPS Continuation (2017-2022), an observational, longitudinal cohort study of KEEPS clinical trial, involved recontacting KEEPS participants approximately 10 years after the completion of the 4-year clinical trial to attend in-person research visits. Seven of the original 9 sites participated in the KEEPS Continuation, resulting in 622 women of original 727 being invited to return for a visit, with 299 enrolling across the 7 sites. KEEPS Continuation participants repeated the original KEEPS-Cog test battery which was analyzed using 4 cognitive factor scores and a global cognitive score. Cognitive data from both KEEPS and KEEPS Continuation were available for 275 participants. Latent growth models (LGMs) assessed whether baseline cognition and cognitive changes during KEEPS predicted cognitive performance at follow-up, and whether mHT randomization modified these relationships, adjusting for covariates. Similar health characteristics were observed at KEEPS randomization for KEEPS Continuation participants and nonparticipants (i.e., women not returning for the KEEPS Continuation). The LGM revealed significant associations between intercepts and slopes for cognitive performance across almost all domains, indicating that cognitive factor scores changed over time. Tests assessing the effects of mHT allocation on cognitive slopes during the KEEPS and across all years of follow-up including the KEEPS Continuation visit were all statistically nonsignificant. The KEEPS Continuation study found no long-term cognitive effects of mHT, with baseline cognition and changes during KEEPS being the strongest predictors of later performance. Cross-sectional comparisons confirmed that participants assigned to mHT in KEEPS (oCEE and tE2 groups) performed similarly on cognitive measures to those randomized to placebo, approximately 10 years after completion of the randomized treatments. These findings suggest that mHT poses no long-term cognitive harm; conversely, it provides no cognitive benefit or protective effects against cognitive decline. CONCLUSIONS: In these KEEPS Continuation analyses, there were no long-term cognitive effects of short-term exposure to mHT started in early menopause versus placebo. These data provide reassurance about the long-term neurocognitive safety of mHT for symptom management in healthy, recently postmenopausal women, while also suggesting that mHT does not improve or preserve cognitive function in this population.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Gleason CE, Dowling NM, Kara F, et al. Long-term cognitive effects of menopausal hormone therapy: Findings from the KEEPS Continuation Study. PLoS Med. 2024. PMID: 39570992. doi:10.1371/journal.pmed.1004435

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。